Roche

News

Biogen buys UK gene therapy firm Nightstar for $800m

Biogen has agreed to buy UK-based gene therapy biotech Nightstar, which focuses on using modified viruses as therapies for inherited retinal disorders, in a deal worth $800 million.

Sales & Marketing

Q4 results roundup 2019

With the full year results season drawing to a close, Richard Staines asks who the winners were and who has been left playing catch-up.

News

Roche to buy gene therapy firm Spark for $4.8 billion

Roche is to buy gene therapy firm Spark Therapeutics for $4.8 billion, adding an already-approved treatment for inherited blindness to its portfolio, and boosting its pipeline with a series

Views & Analysis

Market access roundup: UK HTA shakeups as Brexit fears deepe...

With a Brexit deal still out of sight, there have been intensified warnings in the UK about potential disruptions to medicine supplies that could follow a no-deal scenario.

News

Merck adds to I-O stable with $300m Immune Design buy

Just a few months after Immune Design saw its shares crater on a phase II fail, Merck & Co/MSD has agreed a deal to acquire the biotech and its immuno-oncology and vaccines pipeline.

News

Two new cancer Priority Reviews for Roche

Roche has announced that the FDA has granted Priority Review to two of its drugs – personalised lung cancer medicine entrectinib and lymphoma treatment polat

Biogen buys UK gene therapy firm Nightstar for $800m

Q4 results roundup 2019

Roche to buy gene therapy firm Spark for $4.8 billion

Market access roundup: UK HTA shakeups as Brexit fears deepe...

Merck adds to I-O stable with $300m Immune Design buy

Two new cancer Priority Reviews for Roche

AI specialists Enveda and Basecamp rake in the cash

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks